EMA Application withdrawn: Tibsovo (Ivosidenib) — Agios Netherlands B.V.

View source ↗

Summary

The EMA has withdrawn the applicant for Tibsovo (ivosidenib) by Agios Netherlands B.V. for acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Tibsovo (ivosidenib)

Snippet

Status: Application withdrawn. Therapeutic area: Leukemia, Myeloid, Acute. MAH: Agios Netherlands B.V.